Nautilus Biotechnology analyst ratings
Nautilus Biotechnology analyst ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 07/14/2022 | 46.25% | Goldman Sachs | $5 → $4 | Maintains | Neutral |
| 04/13/2022 | 82.82% | Goldman Sachs | $9 → $5 | Maintains | Neutral |
| 01/06/2022 | 192.5% | Morgan Stanley | → $8 | Initiates Coverage On | → Equal-Weight |
| 11/02/2021 | — | Cowen & Co. | Initiates Coverage On | → Outperform | |
| 08/04/2021 | 265.63% | Goldman Sachs | → $10 | Initiates Coverage On | → Neutral |
| 07/13/2021 | 375.32% | Jefferies | → $13 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目标价格变化 | 评级变化 | 上一次/当前评级 |
|---|---|---|---|---|---|
| 07/14/2022 | 46.25% | 高盛 | $5→$4 | 维护 | 中性 |
| 04/13/2022 | 82.82% | 高盛 | $9→$5 | 维护 | 中性 |
| 01/06/2022 | 192.5% | 摩根士丹利 | →$8 | 开始承保 | →等重 |
| 11/02/2021 | - | 考恩公司 | 开始承保 | →跑赢大盘 | |
| 08/04/2021 | 265.63% | 高盛 | →$10 | 开始承保 | →中性 |
| 07/13/2021 | 375.32% | 杰富瑞 | →$13 | 开始承保 | →购买 |
Nautilus Biotechnology Questions & Answers
鹦鹉螺生物技术问答
The latest price target for Nautilus Biotechnology (NASDAQ: NAUT) was reported by Goldman Sachs on July 14, 2022. The analyst firm set a price target for $4.00 expecting NAUT to rise to within 12 months (a possible 46.25% upside). 5 analyst firms have reported ratings in the last year.
高盛于2022年7月14日报道了鹦鹉螺生物科技公司(纳斯达克：NAUT)的最新目标价。这家分析公司将目标价定为4.00美元，预计NOUT将在12个月内上涨(可能上涨46.25%)。去年有5家分析公司公布了评级。
The latest analyst rating for Nautilus Biotechnology (NASDAQ: NAUT) was provided by Goldman Sachs, and Nautilus Biotechnology maintained their neutral rating.
纳斯达克股票代码：NAUT的最新分析师评级由高盛提供，鹦鹉螺生物科技维持中性评级。
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Nautilus Biotechnology, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Nautilus Biotechnology was filed on July 14, 2022 so you should expect the next rating to be made available sometime around July 14, 2023.
分析师在进行了广泛的研究后得出了股票评级，其中包括查阅公共财务报表，与鹦鹉螺生物科技公司的高管和客户交谈，以及听取收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。对鹦鹉螺生物技术的上一次评级是在2022年7月14日提交的，所以你应该预计下一次评级将在2023年7月14日左右的某个时候公布。
While ratings are subjective and will change, the latest Nautilus Biotechnology (NAUT) rating was a maintained with a price target of $5.00 to $4.00. The current price Nautilus Biotechnology (NAUT) is trading at is $2.74, which is out of the analyst's predicted range.
虽然评级是主观的，并将发生变化，但最新的鹦鹉螺生物技术(Naut)评级维持不变，目标价在5.00美元至4.00美元之间。鹦鹉螺生物技术公司(Nautilus Biotech)目前的股价为2.74美元，超出了分析师的预测区间。